Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OR › Clackamas › NPI 1124182902
Hospital

Kaiser Foundation Hospitals

Kaiser Foundation Hospitals was paid $18.00M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is 99283, emergency room visit (moderate) — 45% of everything it billed.

33Billing provider infoKAISER FOUNDATION HOSPITALS
CLACKAMAS, OR 97015
33aNPI1124182902assigned 12/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.00M
24GClaims227,258
24DCodes billed228
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Oregon

Rank by total paid#7 of 17
Median peer was paid$13.35M
This provider vs. median1.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018107,285$7.04M
201939,062$2.82M
20208,204$980K
202110,039$1.14M
202218,492$1.80M
202319,825$2.24M
2024incomplete24,351$1.97M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 45% 27,204 25,238 $8.11M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 12% 9,244 8,784 $2.16M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 6.8% 7,735 7,431 $1.23M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 2.3% 1,201 1,095 $422K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2.3% 3,804 3,607 $405K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.3% 3,798 3,601 $405K
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.1% 2,949 2,706 $385K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.1% 2,280 2,047 $369K
84443 Thyroid stimulating hormone (TSH) 1.6% 5,850 5,581 $288K
88305 Level IV - Surgical pathology, gross and microscopic examination 1.1% 1,397 1,133 $191K
83036 Hemoglobin; glycosylated (A1C) 1.0% 6,589 6,365 $186K
80061 Lipid panel <1% 3,909 3,768 $154K
216 more codes
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 4,451 $147K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 1,987 $146K
80053 Comprehensive metabolic panel <1% 14,991 $146K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 22,361 $145K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 1,184 $125K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 651 $113K
88142 <1% 1,855 $113K
71046 Radiologic examination, chest; 2 views <1% 1,672 $93K
86780 <1% 2,214 $88K
85027 <1% 5,072 $86K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,109 $77K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 1,055 $77K
86003 <1% 263 $76K
77067 Screening mammography, bilateral, including computer-aided detection <1% 256 $76K
87506 <1% 119 $75K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 301 $74K
80048 Basic metabolic panel (calcium, ionized) <1% 3,168 $67K
82728 <1% 2,144 $66K
86803 <1% 1,508 $65K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 2,095 $64K
82607 <1% 1,398 $61K
90472 Immunization administration, each additional vaccine (list separately) <1% 1,070 $55K
87340 <1% 1,679 $53K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 214 $50K
87086 Culture, bacterial; quantitative colony count, urine <1% 2,080 $49K
84702 <1% 1,065 $48K
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up <1% 164 $44K
87653 <1% 397 $39K
82565 <1% 2,571 $38K
87077 <1% 1,432 $37K
81001 <1% 4,751 $36K
76801 <1% 131 $35K
82274 <1% 680 $33K
0502F <1% 427 $32K
81025 <1% 1,684 $31K
87186 <1% 1,117 $29K
83550 <1% 1,100 $29K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 81 $28K
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 1,906 $28K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 234 $25K
87081 <1% 1,233 $24K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 429 $24K
84460 <1% 1,561 $24K
85610 <1% 2,192 $24K
90834 Psychotherapy session, about 45 minutes <1% 144 $23K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 523 $22K
83540 <1% 1,100 $21K
88342 <1% 119 $21K
83516 <1% 603 $21K
88307 <1% 56 $20K
86140 <1% 1,276 $20K
87522 Neg quan hep c or qual rna <1% 152 $19K
87536 <1% 75 $19K
87529 <1% 81 $18K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 31 $17K
90686 <1% 2,210 $17K
80076 <1% 672 $16K
87070 <1% 614 $16K
84439 <1% 577 $16K
84132 <1% 1,176 $15K
90853 Group psychotherapy (other than of a multiple-family group) <1% 367 $15K
84403 <1% 302 $14K
83690 <1% 3,082 $14K
82042 <1% 870 $14K
90837 Psychotherapy session, about an hour <1% 55 $14K
82570 <1% 905 $13K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 54 $13K
83880 <1% 543 $13K
87210 <1% 987 $13K
80069 <1% 509 $12K
92015 Determination of refractive state <1% 428 $12K
88341 <1% 23 $12K
81003 <1% 1,621 $11K
84153 <1% 206 $11K
92004 Ophthalmological services: medical examination and evaluation, comprehensive, new patient <1% 86 $11K
99354 <1% 35 $10K
86850 <1% 1,243 $10K
82746 <1% 227 $9K
86787 <1% 241 $9K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 118 $9K
87631 <1% 70 $8K
82670 <1% 98 $8K
84146 <1% 144 $8K
90670 <1% 78 $8K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 30 $8K
A7034 Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap <1% 65 $8K
84450 <1% 519 $8K
86762 <1% 181 $8K
92227 <1% 259 $7K
84550 <1% 565 $7K
76642 <1% 67 $7K
87205 <1% 564 $7K
86706 <1% 222 $7K
82784 <1% 276 $7K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 47 $7K
83001 <1% 121 $7K
88141 <1% 87 $6K
86704 <1% 169 $6K
83735 <1% 307 $6K
59025 Fetal non-stress test <1% 59 $6K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 15 $6K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 30 $5K
99215 Doctor's office visit, returning patient (complex) <1% 16 $5K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 428 $5K
86200 <1% 133 $5K
83993 <1% 93 $5K
76830 Ultrasound, transvaginal <1% 18 $5K
82105 <1% 219 $5K
86038 <1% 122 $4K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 67 $4K
86480 <1% 106 $4K
G0399 Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation <1% 14 $4K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 240 $4K
84156 <1% 375 $4K
86255 <1% 40 $4K
85652 <1% 473 $4K
86765 <1% 104 $4K
87517 <1% 34 $4K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 13 $3K
73630 <1% 47 $3K
88304 <1% 62 $3K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 15 $3K
A7035 Headgear used with positive airway pressure device <1% 66 $3K
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient <1% 30 $3K
86431 <1% 188 $3K
83002 <1% 54 $3K
82950 <1% 207 $3K
84165 <1% 70 $3K
82550 <1% 163 $3K
99203 Doctor's office visit, new patient (routine) <1% 12 $3K
82248 <1% 222 $3K
84480 <1% 61 $3K
86708 <1% 65 $2K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 42 $2K
82627 <1% 35 $2K
83615 <1% 127 $2K
96375 Therapeutic injection; each additional sequential IV push <1% 154 $2K
86160 <1% 40 $2K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 3,105 $2K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 12 $2K
86360 <1% 13 $2K
81507 <1% 170 $2K
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 90 $2K
71250 <1% 12 $2K
82951 <1% 80 $2K
82533 <1% 37 $2K
95806 <1% 15 $2K
83970 <1% 15 $2K
82247 <1% 126 $2K
86696 <1% 27 $2K
86735 <1% 41 $2K
86709 <1% 44 $2K
83021 <1% 28 $2K
90698 <1% 13 $2K
82040 <1% 116 $2K
86376 <1% 35 $1K
87329 <1% 41 $1K
87209 <1% 25 $1K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 180 $1K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 131 $1K
84100 <1% 106 $1K
72100 <1% 14 $1K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 12 $1K
73030 <1% 19 $1K
84295 <1% 93 $1K
86695 <1% 28 $1K
82947 <1% 97 $1K
84075 <1% 75 $1K
81002 <1% 135 $1K
73502 <1% 12 $978.00
87449 <1% 29 $977.00
87324 <1% 28 $962.00
80178 <1% 51 $960.00
85730 <1% 60 $954.00
86592 <1% 76 $931.00
74018 <1% 13 $898.00
92504 <1% 15 $882.00
87338 <1% 112 $878.00
J3490 Unclassified drugs <1% 13,579 $856.74
99441 <1% 26 $840.00
86361 <1% 17 $825.00
86900 <1% 255 $773.51
86901 <1% 255 $762.63
87101 <1% 31 $759.00
81050 <1% 67 $751.00
11721 <1% 16 $737.00
87177 <1% 25 $702.00
86308 <1% 41 $661.00
73610 <1% 14 $642.00
87040 <1% 14 $640.00
87075 <1% 20 $557.00
J7120 Ringers lactate infusion, up to 1000 cc <1% 336 $546.74
A7037 Tubing used with positive airway pressure device <1% 46 $545.00
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 14 $512.00
82390 <1% 14 $462.00
83655 <1% 88 $446.00
82340 <1% 29 $432.00
84402 <1% 67 $402.00
85014 <1% 60 $399.00
85018 <1% 58 $385.00
84520 <1% 32 $360.00
71045 Radiologic examination, chest; single view <1% 14 $293.00
82465 <1% 27 $286.00
82103 <1% 35 $245.00
82435 <1% 16 $210.00
85007 <1% 17 $165.00
85045 <1% 12 $144.00
J3010 Injection, fentanyl citrate, 0.1 mg <1% 68 $69.81
J7030 Infusion, normal saline solution , 1000 cc <1% 661 $50.58
84484 <1% 683 $49.38
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program <1% 235 $0.07
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) 0% 77 $0.00
96152 0% 18 $0.00
J1885 Injection, ketorolac tromethamine, per 15 mg 0% 173 $0.00
A9270 Non-covered item or service 0% 319 $0.00
83605 0% 17 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBARTON, SHAWN (EXECUTIVE DIRECTOR, REVENUE CYCLE)
Parent organizationKAISER FOUNDATION HOSPITALS
Same official

Other billing entities under BARTON, SHAWN

Full network →
ProviderLocationPaid
Kaiser Foundation HospitalsPortland, OR$2.33M
Kaiser Foundation HospitalsClackamas, OR$1.93M
Kaiser Foundation HospitalsClackamas, OR$1.82M
Kaiser Foundation HospitalsSalem, OR$0.00
Kaiser Foundation HospitalsClackamas, OR$0.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.